{"abstract":"The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Taurgen Malaria, Inc. (\"Taurgen\"), headquartered in Logan, UT. Taurgen Malaria, Inc. is a wholly-owned subsidiary of Taurgen Therapeutics, LLC, which is also headquartered in Logan, UT.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/03/20/2024-05878.html","cfr_references":[],"citation":"89 FR 19855","comment_url":null,"comments_close_on":"2024-04-04","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before April 4, 2024 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2024-05878","effective_on":null,"end_page":19856,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/03/20/2024-05878.xml","html_url":"https://www.federalregister.gov/documents/2024/03/20/2024-05878/prospective-grant-of-an-exclusive-patent-license-manufacturing-of-anti-malaria-monoclonal-antibody","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-05878?publication_date=2024-03-20","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-03-20/2024-05878/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":94,"last_updated":"2026-07-27 16:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-03-20/pdf/2024-05878.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-05878.pdf?1710852329","publication_date":"2024-03-20","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/03/20/2024-05878.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2024-03-20T08:09:30Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":19855,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Manufacturing of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep","toc_doc":"Manufacturing of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.:\n","topics":[],"type":"Notice","volume":89}